source
- Amgen ends $500M Crohn’s disease collaboration with TScan, but TScan says pipeline strategy stays on trackAmgen has terminated its collaboration with TScan Therapeutics that was aimed at Crohn’s disease, ending a deal that could have delivered up to $500 million in milestones. The partnership began in…
- Merck and Moderna’s personalized mRNA vaccine shows longer recurrence-free survival in phase 3 melanoma trialMerck and Moderna reported that their individualized mRNA cancer vaccine, given together with Keytruda, extended the time patients remained free of melanoma recurrence in a late-stage study. The p…